Incyte (Nasdaq:INCY) announces the appointment of Katherine High, M.D., as a new member of the Board of Directors, effective March 25, 2020.
"We are delighted to announce that Kathy is joining the Incyte Board of Directors. Her scientific expertise and extensive leadership experience will support and enhance Incyte’s continued growth," said Hervé Hoppenot, Chief Executive Officer, Incyte.
"This is an exciting time to be joining Incyte – with the potential for three new product approvals this year, the Company’s discovery, development and strategic focus continue to drive the delivery of innovative solutions for patients in need," said Dr. High. "I look forward to joining what is already an immensely talented and diverse team."
From 2014 to 2020, Dr. High held several key executive positions at Spark Therapeutics, Inc., a gene therapy company, including President, Head of Research and Development and Chief Scientific Officer. Prior to joining Spark, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania and an Investigator at the Howard Hughes Medical Institute. Additionally, from 2004 to 2014, Dr. High served as the Director of the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia. Dr. High served a five-year term on the FDA Advisory Committee on Cell, Tissue and Gene Therapies, and was a past president of the American Society of Gene & Cell Therapy (ASGCT). She received her A.B. in chemistry from Harvard University, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an M.A. from the University of Pennsylvania.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including without limitation statements regarding the Company’s efforts to advance its clinical pipeline, improve the lives of patients and build value for stakeholders contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including risks related to market competition, the results of and risks associated with research and development, risks and uncertainties associated with sales, marketing and distribution requirements, and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914